Aurion Biotech, Inc. (AURN)

Aurion Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Net Income	-59.92	-45.55	-35.69
Depreciation & Amortization	0.7	0.56	1.27
Share-Based Compensation	-	3.98	2.39
Other Operating Activities	7.34	-0.36	-0.32
Operating Cash Flow	-51.88	-41.37	-32.35
Capital Expenditures	-0.79	-1.24	-1.51
Investing Cash Flow	-0.79	-1.24	-1.51
Share Issuance / Repurchase	-	65.26	52.22
Debt Issued / Paid	-	-	-8.35
Financing Cash Flow	56.52	65.26	43.87
Net Cash Flow	3.98	22.48	9.98
Free Cash Flow	-52.67	-42.61	-33.86

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).